Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 18/20 | 0.80 |
| ▸ | JAK2 | O60674 | 4/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.64 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.64 |
| ▸ | PLK4 | O00444 | 2/20 | 0.64 |
| ▸ | AURKA | O14965 | 2/20 | 0.64 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.64 |
| ▸ | INSR | P06213 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | FES | P07332 | 2/20 | 0.64 |
| ▸ | CSF1R | P07333 | 2/20 | 0.64 |
| ▸ | LYN | P07948 | 2/20 | 0.64 |
| ▸ | RET | P07949 | 2/20 | 0.64 |
| ▸ | IGF1R | P08069 | 2/20 | 0.64 |
| ▸ | ROS1 | P08922 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | FER | P16591 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843177 | 0.91 | MET (0.66) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL6104605 | 0.91 | MET (0.85) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL1582053 | 0.91 | MET (0.80) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL1581972 | 0.90 | MET (0.81) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL1581478 | 0.89 | MET (1.00) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL1582245 | 0.88 | MET (0.81) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL15289316 | 0.87 | MET (0.74) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL488614 | 0.86 | MET (0.74) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL30453245 | 0.86 | MET (0.74) | METJAK2ALKMAP4K3PLK4 | |
| SCHEMBL1582362 | 0.86 | MET (1.00) | METJAK2ALKMAP4K3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784396-B1 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-1784396-B1 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | MET 1/4885JAK2 249/4885ALK 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.